BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test
RICHMOND, Va., Oct. 4, 2022 /PRNewswire/ -- BRAINBox Solutions, Inc announced today that the U.S. Patent & Trademark Office (PTO) issued a notice of allowance for a patent covering methods for detection of mild traumatic brain injury (mTBI), also known as concussion, using Brain Derived Neurotrophic Factor (BDNF). BDNF is an important component of the biomarker panel in the multi-modal diagnostic prognostic and prognostic solutions the company is developing for mTBI.
- "BRAINBox's test is the first to integrate blood biomarkers with functional testing for both the diagnosis and prognosis of mild TBI," said Donna Edmonds, BRAINBox Solutions' Chief Executive Officer.
- "The new BDNF patent is an important addition to our broad, worldwide portfolio of patents covering biomarkers related to various aspects of diagnostic use.
- The newly allowed patent is based on BRAINBox Solutions' discovery that a decrease in blood levels of BDNF alone are sensitive and specific in the detection of mild TBI.
- BRAINBox Solutions is developing the first AI enabled, multi-modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion.